EBiSC2

EBiSC2 – A sustainable European bank for induced pluripotent stem cells
EBISC2 logo

FACTS & FIGURES

Start Date
End Date
Call
IMI2 - Call 13
Grant agreement number
821362

Type of Action: 
RIA (Research and Innovation Action)

Contributions
IMI Funding
4 599 648
EFPIA in kind
4 272 964
Total Cost
8 872 548

Summary

Induced pluripotent stem cells (iPSCs) are key tools for early drug development and disease modelling. IPSCs are mature adult cells that have been reprogrammed to make them ‘pluripotent’, i.e. able to differentiate into any type of cell found in the human body.

EBiSC2 aims to become a self-sustaining biobank, providing well-characterised, quality controlled iPSCs to the academic and industrial scientific communities worldwide. Building on the work of previous projects, including IMI’s EBiSC, EBiSC2 will provide access to a broad catalogue of iPSCs from diverse disease and genetic backgrounds along with comprehensive datasets. They will also offer the bulk production of iPSCs and the delivery of pre-differentiated cell populations. By supporting future iPSC-based disease research, EBiSC2 will contribute to the discovery and development of new drugs.

Participants Show participants on map

EFPIA companies
  • Bayer Aktiengesellschaft, Leverkusen, Germany
  • Eli Lilly and Company Limited, Basingstoke, United Kingdom
  • Fujifilm Cellular Dynamics Inc, Madison, United States
  • H. Lundbeck As, Valby, Denmark
  • Institut De Recherches Servier, Suresnes, France
  • Janssen Pharmaceutica Nv, Beerse, Belgium
  • Novo Nordisk A/S, Bagsvaerd, Denmark
  • Pfizer Limited, Sandwich, Kent , United Kingdom
  • Takeda Development Centre Europe LTD., London, United Kingdom
  • UCB Biopharma SPRL, Brussels, Belgium
Universities, research organisations, public bodies, non-profit groups
  • Bioneer A/S, Horsholm, Denmark
  • Charite - Universitaetsmedizin Berlin, Berlin, Germany
  • Department of Health, Leeds, United Kingdom
  • Fraunhofer Gesellschaft Zur Foerderung Der Angewandten Forschung E.V., München, Germany
  • Katholieke Universiteit Leuven, Leuven, Belgium
Small and medium-sized enterprises (SMEs) and mid-sized companies (<€500 m turnover)
  • Arttic, Paris, France
Third parties
  • Fraunhofer Uk Research Limited, Glasgow, United Kingdom

CONTACT

Project coordinator
Heiko ZIMMERMANN
FRAUNHOFER GESELLSCHAFT ZUR FOERDERUNG DER ANGEWANDTEN FORSCHUNG E.V.
heiko.zimmermann[at]ibmt.fraunhofer.de